With the low penetrance of LRRK2 mutations for development of PD (estimated 25–40% for G2019S LRRK2 [13]), it is clear that there is still much to uncover regarding the pathogenicity of LRRK2 mutations and their interaction with other modulators of disease penetrance. The gene discussed is LRRK2; the disease is Parkinson disease.